Therefore, we suggest that, in future trials, dual TIM-3 and PD-1/PD-L1 inhibition should be considered for patients with CMS4 and MSI CRC, where TIM-3 is highly expressed in the TGFβ-rich TME. The gene discussed is PDCD1; the disease is colorectal carcinoma.